Impax Laboratories Increases Sales but Misses Revenue Estimate

Just the facts, Fool.

Impax Laboratories (Nasdaq: IPXL) reported earnings on Oct. 30. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Impax Laboratories missed estimates on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share increased.

Gross margins grew, operating margins contracted, net margins shrank.

Revenue details
Impax Laboratories logged revenue of $145.6 million. The 14 analysts polled by S&P Capital IQ wanted to see revenue of $161.4 million on the same basis. GAAP reported sales were 21% higher than the prior-year quarter's $119.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.48. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.48 per share. GAAP EPS of $0.29 for Q3 were 12% higher than the prior-year quarter's $0.26 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 53.6%, 130 basis points better than the prior-year quarter. Operating margin was 20.0%, 290 basis points worse than the prior-year quarter. Net margin was 13.8%, 60 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $166.2 million. On the bottom line, the average EPS estimate is $0.44.

Next year's average estimate for revenue is $637.2 million. The average EPS estimate is $2.03.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 169 members out of 185 rating the stock outperform, and 16 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Impax Laboratories a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is outperform, with an average price target of $25.59.

Add Impax Laboratories to My Watchlist.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Impax Laboratories Inc.

IPXL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

454%

S&P 500 Returns

122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/31/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Impax Laboratories Increases Sales but Misses Revenue Estimate

NASDAQ: IPXL